Zoll acquired Kyma Medical Technologies, a Tel Aviv, Israel-based developer of technologies to measure early signs of congestive heart failure. Terms of the deal were not announced.
Kymia is developing a remote patient monitoring system that uses radio frequency-based technology to detect and monitor the level of fluid in the lungs and collects data on heart rate, respiration rate, activity and posture. The system then analyzes the information via an algorithm to determine vital signs trends in patients and sends a notification to the patients’ medical team if their condition deteriorates, according to a news release announcing the acquisition.
The system is not FDA-approved, although it is approved in Europe to monitor thoracic fluid content, ECG, heart rate, respiration rate, activity and posture.
Zoll specializes in developing medical devices and software for resuscitation and acute and emergency care. The company has products for defibrillation and monitoring, circulation and CPR feedback, data management, ventilation, fluid resuscitation and therapeutic temperature management.